Philippe Peltier
Partner @ Kurma Partners
Paris, France
Philippe Peltier is a Series A investor at Kurma Partners in Paris focused on Health Care and Biotechnology. Philippe has been a Partner at Auriga Partners since 1999. Philippe has been an early stage investor in numerous successful healthcare companies including Alantos Pharmaceuticals (acquired by Amgen), Innate Pharma (EuroNext Paris: IPH), Spine Next (acquired by Abbott), Targacept (Nasdaq: TRGT), Tigenix (EuroNext : TIG). He currently serves onthe board of directors of several portfolio companies including, Novagali Pharma (France) and Genocea Biosciences (Etats-Unis). Prior to joining Auriga Partners, Philippe was an equity analyst with HSBC-CCF Securities, covering biotech and biopharma public stocks. He holds a MS in Molecular Biology from the University of Paris VII and a MS in finance from ESSEC (Paris).
- Total investments:
- 17
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Philippe Peltier invests in
Stages Philippe Peltier invests in
Countries Philippe Peltier invests in
Investment Focus
Industry
- Health Care 7 (41%)
- Biotechnology 6 (35%)
- Medical 4 (24%)
- Medical Device 4 (24%)
- Big Data 1 (6%)
Stage
- Series A 5 (29%)
- Seed 3 (18%)
- Series B 3 (18%)
- Series C 2 (12%)
- Series D 1 (6%)
Country
- France 7 (41%)
- Belgium 1 (6%)
- United States 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sunrise
|
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M / Sep 25, 2025 | |
Stilla Technologies
|
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $26.5M / Series C / Feb 22, 2024 | |
|
Sunrise
|
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $18M / Series A / Mar 09, 2023 | |
DAMAE Medical
|
Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis. | $5.7M / Series A / Feb 03, 2022 | |
|
Sunrise
|
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $7.3M / Seed / Dec 15, 2021 | |
|
Stilla Technologies
|
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $34.9M / Debt Financing / Nov 23, 2021 | |
DNA Script
|
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M / Series C / Oct 26, 2021 | |
Lucine
|
Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement andanalysis of the pain by facial, vocal and postural recognition. | $5.8M / Seed / Nov 18, 2020 | |
|
Stilla Technologies
|
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $21.8M / Series B / Feb 11, 2020 | |
Sensome
|
Sensome develops a breakthrough remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices. By providing instantaneous and non-invasive identification of the tissue composition in contact with a medical device, Sensome's patent-pending sensor technology overcomes the limitations of vascularimaging techniques used in both interventions and patient follow-up. Sensome's team is currently developing vascular access devices equipped with the proprietary sensor technology, before eventually equipping implantable devices for neurovascular, peripheral vascular and cardiovascular indications. | $8.8M / Series B / Jan 12, 2020 | |
| See all 17 investments → | |||
Co-Investors
About Kurma Partners
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Kurma Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Horvais
Partner
|
|||
Amanda Gett Chaperot
Partner
|
|||
Amine Marouf
Principal
|
|||
Peter Neubeck
Partner
|
|||
|
Philippe Peltier
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Philippe Peltier invest in?
Philippe Peltier invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Philippe Peltier last invest?
The most recent investment recorded for Philippe Peltier closed in Sep 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
